4/A: Sensus Healthcare exec buys 2,000 shares

President and General Counsel Michael Sardano reported open-market purchases totaling 2,000 SRTS shares on Nov. 11, 2025, including 1,000 directly and 1,000 by his spouse.

Summary

• Michael Sardano, President, General Counsel and Director of Sensus Healthcare (SRTS), reported open-market purchases on 11/11/2025.
• Direct purchase: 1,000 common shares at $4.26 per share; post-transaction direct holdings: 117,839 shares.
• Indirect (spouse) purchases: 766 shares at $4.27 and 234 shares at $4.34; post-transaction spouse holdings: 1,000 shares.
• Sardano disclaims beneficial ownership of spouse-held shares.
• This is an amended Form 4; the original was filed on 11/13/2025 and the amendment is signed 11/18/2025.
• No derivative securities were reported.

Sentiment

Score: 6

Explanation: Modestly positive signal due to insider buying and no sales, though the dollar amount is small and spouse-owned shares are disclaimed.

Positives

• Insider buying: 1,000 shares purchased directly by the executive at $4.26.
• Additional insider-related buying: spouse purchased 1,000 shares at weighted prices of $4.27 and $4.34 (beneficial ownership disclaimed).
• No insider sales were reported.
• Direct ownership increased to 117,839 shares.

Negatives

• Purchase size is modest in dollar terms (approximately $4,260 directly and ~$4,300 by spouse).
• The executive disclaims beneficial ownership of the spouse’s 1,000 shares, limiting alignment from those shares.

Future Outlook

No forward-looking statements or guidance provided.

Management Comments

• Shares held by Mr. Sardano’s spouse, as to which he disclaims beneficial ownership.

Industry Context

Insider open-market purchases in small- and mid-cap medtech are commonly interpreted as a modest vote of confidence but are not, by themselves, indicative of operational performance or outlook.

Comparison to Industry Standards

• The purchase size (roughly $4–9k combined direct and spouse) is typical of routine insider accumulation seen across small-cap medtech peers (e.g., Accuray, iCAD) and is not large enough to constitute a strong signal relative to sector norms.
• Absence of derivative transactions aligns with standard open-market insider purchase practices, offering clearer alignment but limited informational value compared to large multi-tranche insider buys seen at some peers.

Related Party Transactions

• 1,000 shares are held by Mr. Sardano’s spouse; Mr. Sardano disclaims beneficial ownership of those shares.

Stakeholder Impact

• Shareholders may view modest insider buying as a confidence signal.
• No dilution or balance sheet impact since purchases were open-market.

Key Dates

Keywords

Sensus Healthcare, SRTS, Form 4/A, insider buying, Michael Sardano, beneficial ownership, open-market purchase, President and General Counsel, director transaction, SEC filing